Speculative strategies for new antibacterials: All roads should not lead to Rome

Journal of Antibiotics

Volumn 66, Issue 7, 2013, Pages 371-386

  Shapiro, Stuart ^a  

^a Harry Lime Institute for Penicillin Research   (Switzerland)

Author keywords

antimetabolites; hybrid antibiotics; methyltransferase inhibitors; polymyxins; toxinantitoxins

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; ANTITOXIN; AVIDIN; CADAZOLID; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FIDAXOMICIN; FLAVINE MONONUCLEOTIDE; LFF 571; LINEZOLID; METHYLTRANSFERASE INHIBITOR; METRONIDAZOLE; NVB 302; POLYMYXIN; QUINOLONE DERIVATIVE; RAMOPLANIN; RIFAMPICIN; RIFAMYCIN; RIFAXIMIN; SULFAMIDOCHRYSOIDINE; SUROTOMYCIN; TD 1792; TOXIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; BACTERIAL CHROMOSOME; BINDING AFFINITY; BINDING SITE; BIOSYNTHESIS; BRUSH BORDER; CELL FUNCTION; CHLAMYDIA TRACHOMATIS; CLOSTRIDIUM DIFFICILE INFECTION; COMBINATORIAL CHEMISTRY; COMPETITIVE INHIBITION; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG SYNTHESIS; DRUG TARGETING; ENTEROCOCCUS FAECALIS; HUMAN; IC 50; IN VITRO STUDY; KIDNEY TUBULE EPITHELIUM; LUNG FIBROBLAST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPEN READING FRAME; PHARMACOPHORE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; ANTIMETABOLITES; BACTERIA; METABOLIC NETWORKS AND PATHWAYS;

EID: 84880996459     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2013.27     Document Type: Review

References (200)

1. Infectious Diseases Society of America Bad bugs, no drugs. As antibiotic discovery stagnates. a public health crisis brews (Infect. Dis. Soc. Am., Alexandria, VA, USA, 2004).
2. European Centre for Disease Prevention and Control & European Medicines Agency The bacterial challenge: time to react. A call to narrow the gap between multidrug-resistant bacteria in the EU and the development of new antibacterial agents. (ECDC/EMEA Joint Technical Report, EMEA/576176/2009) (ECDC, Stockholm, Sweden, 2009).
3. Nugent, R., Back, E. & Beith., A. The race against drug resistance (Center for Global Development's Drug Resistance Working Group, Washington, DC, USA, 2010).
4. World Health Organization The evolving threat of antimicrobial resistance-options for action (WHO, Geneva, Switzerland, 2012).
5. Dellit, T. H. et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis. 44, 159-177 (2007).
6. Appelbaum, P. C. 2012 and beyond: potential for the start of a second pre-antibiotic era? J. Antimicrob. Chemother. 67, 2062-2068 (2012).
7. Kluytmans, J. The emergence of resistant Gram-negative bacteria-are we entering the post-antibiotic era? Eur. Infect. Dis. 6, 19-21 (2012).
8. Shapiro, S. (ed) Regulation of Secondary Metabolism in Actinomycetes (CRC Press, Inc., Boca Raton, FL, USA, 1989).
9. Shapiro, S. & Guggenheim, B. in Oral Biology at the Turn of the Century: Misconceptions, Truths, Challenges and Prospects (eds Guggenheim, B. & Shapiro, S.) 226-238 (S. Karger AG, Basel, Switzerland, 1998).
10. Katz, L. & Donadio, S. Polyketide synthesis: prospects for hybrid antibiotics. Annu. Rev. Microbiol. 47, 875-912 (1993).
11. Běhal, V. Hybrid antibiotics. Folia Microbiol. 48, 17-25 (2003).
12. Pokrovskaya, V. & Baasov, T. Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance. Expert Opin. Drug Discov. 5, 883-902 (2010).
13. Hagihara, M., Crandon, J. L. & Nicolau, D. P. The efficacy and safety of antibiotic combination therapy for infections caused by Gram-positive and Gram-negative organisms. Expert Opin. Drug Saf. 11, 221-233 (2012).
14. Chu, C. K. & Bardos, T. J. Synthesis and inhibition analysis of 2(4)-imino-4(2)-amino-2, 4-dideoxyriboflavin, a dual antagonist of riboflavin and folinic acid. J. Med. Chem. 20, 312-314 (1977).
15. Long, D. D. & Marquess, D. G. Novel heterodimer antibiotics: a review of recent patent literature. Future Med. Chem. 1, 1037-1050 (2009).
16. Karoli, T. et al. Structure aided design of chimeric antibiotics. Bioorg. Med. Chem. Lett. 22, 2428-2433 (2012).
17. Livermore, D. M. Linezolid in vitro: mechanism and antibacterial spectrum. J. Antimicrob. Chemother. 51 (Suppl. 2), ii9-ii16 (2003).
18. Jacoby, G. A. Mechanisms of resistance to quinolones. Clin. Infect. Dis. 41 (Suppl. 2), S120-S126 (2005).
19. Okusu, H., Ma, D. & Nikaido, H. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic- resistance (Mar) mutants. J. Bacteriol. 178, 306-308 (1996).
20. Poole, K. Efflux-mediated multiresistance in Gram-negative bacteria. Clin. Microbiol. Infect. 10, 12-26 (2004).
21. Robertson, G. T. et al. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. Anti-microb. Agents Chemother. 52, 2313-2323 (2008).
22. Weintraub, A. et al. Cadazolid and fidaxomicin are active against strains isolated from primary and recurrent Clostridium difficile infections. Clin. Microbiol. Infect. 18 (Suppl. 3), 659 (2012).
23. Locher, H. H. et al. Cadazolid, a novel quinolonyl-oxazolidinone antibiotic with potent activity against Clostridium difficile: in vitro antibacterial activity and propensity for resistance development. Abstracts of Papers of 52nd Intersci. Conf. on Antimicrob. Agents Chemother. No. C1-1346, San Francisco, CA, USA (2012).
24. Hecht, D. W., Gerding, D. N., Osmolski, J. R., Sambol, S. & Cheknis, A. In vitro activity of cadazolid against 209 toxigenic isolates of Clostridium difficile. Abstracts of Papers of 52nd Intersci. Conf. on Antimicrob. Agents Chemother. No. E-808 (San Francisco, CA, USA, 2012).
25. Baldoni, D., Gutierrez, M., Dingemanse, J. & Timmer, W. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability, and pharmaco-kinetics in healthy subjects following single and multiple oral doses. Abstracts of Papers of 52nd Intersci. Conf. on Antimicrob. Agents Chemother. No. A-1273 (San Francisco, CA, USA, 2012).
26. Locher, H. H. et al. Cadazolid, a novel quinolonyl-oxazolidinone antibiotic: mode of action and effect on Clostridium difficile toxin and spore formation. Abstracts of Papers of 52nd Intersci. Conf. on Antimicrob. Agents Chemother. No. C1-1347 (San Francisco, CA, USA, 2012).
27. Hubschwerlen, C., Specklin, J. L., Sigwalt, C., Schroeder, S. & Locher, H. H. Design, synthesis and biological evaluation of oxazolidinone-quinolone hybrids. Bioorg. Med. Chem. 11, 2313-2319 (2003).
28. McKee, E. E., Ferguson, M., Bentley, A. T. & Marks, T. A. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob. Agents Chemother. 50, 2042-2049 (2006).
29. Owens, R. C. Jr. & Ambrose, P. G. Antimicrobial safety: focus on fluoroquinolones. Clin. Infect. Dis. 41 (Suppl. 2), S144-S157 (2005).
30. Pugi, A. et al. Cardiovascular and metabolic safety profiles of the fluoroquinolones. Expert Opin. Drug Saf. 11, 53-69 (2012).
31. Lapi, F. et al. Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clin. Infect. Dis. 55, 1457-1465 (2012).
32. Paterson, J. M., Mamdani, M. M., Manno, M. & Juurlink, D. N. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study. Can. Med. Assoc. J. 184, 1565-1570 (2012).
33. Vardakas, K. Z., Konstantelias, A. A., Loizidis, G., Rafailidis, P. I. & Falagas, M. E. Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis. Int. J. Infect. Dis. 16, e768-e773 (2012).
34. van Nood, E. et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407-415 (2013).
35. Pokrovskaya, V., Belakhov, V., Hainrichson, M., Yaron, S. & Baasov., T. Design, synthesis, and evaluation of novel fluoroquinolone-aminoglycoside hybrid antibiotics. J. Med. Chem. 52, 2243-2254 (2009).
36. Asahina, Y., Nagae, O. & Sato, T. AM-3005: synthesis and in vitro antibacterial activity of novel mutilin-quinolone hybrid antibacterial agent. Abstracts of Papers of 48th Intersci. Conf. on Antimicrob. Agents Chemother. No. F1-2030 (Washington, DC, USA, 2008).
37. Li, Q. et al. NB2001, a novel antibacterial agent with broad-spectrum activity and enhanced potency against b-lactamase-producing strains. Antimicrob. Agents Chemother. 46, 1262-1268 (2002).
38. Gutmann, L., al-Obeid, S., Billot-Klein, D., Guerrier, M.-L. & Collatz, E. Synergy and resistance to synergy between b-lactam antibiotics and glycopeptides against glycopeptide-resistant strains of Enterococcus faecium. Antimicrob. Agents Chemother. 38, 824-829 (1994).
39. Ravizzola, G. et al. In-vitro study of the synergy between b-lactam antibiotics and glycopeptides against enterococci. J. Antimicrob. Chemother. 39, 461-470 (1997).
40. Long, D. D. et al. Exploring the positional attachment of glycopeptide/b-lactam heterodimers. J. Antibiot. 61, 603-614 (2008).
41. Poe, M. Antibacterial synergism: a proposal for chemotherapeutic potentiation between trimethoprim and sulfamethoxazole. Science 194, 533-535 (1976).
42. Osborne, R. First novel anti-tuberculosis drug in 40 years. Nat. Biotechnol. 31, 89-91 (2013).
43. Blais, J., Lewis, S. R., Krause, K. M. & Benton, B. M. Antistaphylococcal activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic. Antimicrob. Agents Chemother. 56, 1584-1587 (2012).
44. Tyrrell, K. L., Citron, D. M., Warren, Y. A. & Goldstein, E. J. In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species. Antimicrob. Agents Chemother. 56, 2194-2197 (2012).
45. Craig, W. A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26, 1-10 (1998).
46. Hegde, S. S. et al. Pharmacodynamics of TD-1792, a novel glycopeptide-cephalos-porin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh model. Antimicrob. Agents Chemother. 56, 1578-1583 (2012).
47. Stryjewski, M. E. et al. TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections. Antimicrob. Agents Chemother. 56, 5476-5483 (2012).
48. Schlünzen, F. et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature 413, 814-821 (2001).
49. Hansen, J. L., Moore, P. B. & Steitz, T. A. Structures of five antibiotics bound at the peptidyl transferase center of the large ribosomal subunit. J. Mol. Biol. 330, 1061-1075 (2003).
50. BK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell 121, 257-270 (2005).
51. Dunkle, J. A., Xiong, L., Mankin, A. S. & Cate, J. H. Structures of the Escherichia coli ribosome with antibiotics bound near the peptidyl transferase center explain spectra of drug action. Proc. Natl Acad. Sci. USA 107, 17152-17157 (2010).
52. Bulkley, D., Innis, C. A., Blaha, G. & Steitz, T. A. Revisiting the structures of several antibiotics bound to the bacterial ribosome. Proc. Natl Acad. Sci. USA 107, 17158-17163 (2010).
53. Fernandez-Muñoz, R., Monro, R. E., Torres-Pinedo, R. & Vazquez, D. Substrate-and antibiotic-binding sites at the peptidyl-transferase centre of Escherichia coli ribosomes. Studies on the chloramphenicol, lincomycin and erythromycin sites. Eur. J. Biochem. 23, 185-193 (1971).
54. Moazed, D. & Noller, H. F. Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA. Biochimie 69, 879-884 (1987).
55. Zemlička, J. & Bhuta, A. Sparsophenicol: a new synthetic hybrid antibiotic inhibiting ribosomal peptide synthesis. J. Med. Chem. 25, 1123-1125 (1982).
56. Zemlička, J. et al. Hybrids of antibiotics inhibiting protein synthesis. Synthesis and biological activity. J. Med. Chem. 36, 1239-1244 (1993).
57. Williams, D. H. & Bardsley, B. The vancomycin group of antibiotics and the fight against resistant bacteria. Angew. Chem. Int. Ed. 38, 1172-1193 (1999).
58. Griffin, J. H. et al. Multivalent drug design. Synthesis and in vitro analysis of an array of vancomycin dimers. J. Am. Chem. Soc. 125, 6517-6531 (2003).
59. Fonseca, C. D., Watanabe, M. & Vattimo, M. de F. F. Role of heme oxygenase-1 in polymyxin B-induced nephrotoxicity in rats. Antimicrob. Agents Chemother. 56, 5082-5087 (2012).
60. Barnett, M., Bushby, S. R. & Wilkinson, S. Sodium sulphomethyl derivatives of polymyxins. Br. J. Pharmacol. Chemother. 23, 552-574 (1964).
61. Elemam, A., Rahimian, J. & Doymaz, M. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J. Clin. Microbiol. 48, 3558-3562 (2010).
62. Abdelraouf, K. et al. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob. Agents Chemother. 56, 4625-4629 (2012).
63. Nation, R. L. & Li, J. Optimizing use of colistin and polymyxin B in the critically ill. Semin. Respir. Crit. Care Med. 28, 604-614 (2007).
64. Bergen, P. J., Li, J. & Nation, R. L. Dosing of colistin-back to basic PK/PD. Curr. Opin. Pharmacol. 11, 464-469 (2011).
65. Dalfino, L. et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin. Infect. Dis. 54, 1720-1726 (2012).
66. Bergen, P. J. et al. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new? Diagn. Microbiol. Infect. Dis 74, 213-223 (2012).
67. Quale, J. et al. Activity of polymyxin B and the novel polymyxin analogue CB-182, 804 against contemporary Gram-negative pathogens in New York City. Microb. Drug. Resist. 18, 132-136 (2012).
68. Bennett, W. M., Wood, C. A., Houghton, D. C. & Gilbert, D. N. Modification of experimental aminoglycoside nephrotoxicity. Am. J. Kidney Dis. 8, 292-296 (1986).
69. Humes, H. D. Aminoglycoside nephrotoxicity. Kidney Int. 33, 900-911 (1988).
70. Bosmans, J.-L. & De Broe, M. E. in Diseases of the Kidney and Urinary Tract (ed Schrier, R. W.) 8th edn., vol. 2, 1035-1067 (Lippincott Williams & Wilkins, Philadelphia, PA, USA, 2007).
71. Williams, P. D., Bennett, D. B., Gleason, C. R. & Hottendorf, G. H. Correlation between renal membrane binding and nephrotoxicity of aminoglycosides. Antimicrob. Agents Chemother. 31, 570-574 (1987).
72. Vaara, M. et al. Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob. Agents Chemother. 52, 3229-3236 (2008).
73. Ali, F. E. et al. Pharmacokinetics of novel antimicrobial cationic peptides NAB 7061 and NAB 739 in rats following intravenous administration. J. Antimicrob. Chemother. 64, 1067-1070 (2009).
74. Mingeot-Leclercq, M. P., Tulkens, P. M., Denamur, S., Vaara, T. & Vaara, M. Novel polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells. Peptides 35, 248-252 (2012).
75. Vaara, M. & Vaara, T. The novel polymyxin derivative NAB739 is remarkably less cytotoxic than polymyxin B and colistin to human kidney proximal tubular cells. Int. J. Antimicrob. Agents 41, 292-293 (2013).
76. Vaara, M., Sader, H. S., Rhomberg, P. R., Jones, R. N. & Vaara, T. Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens. J. Antimicrob. Chemother. 68, 636-639 (2013).
77. Vingsbo Lundberg, C., Vaara, T., Frimodt-Møller, N. & Vaara, M. Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice. J. Antimicrob. Chemother. 65, 981-985 (2010).
78. Dalhoff, A. A. H. Discovery and development of anti-infectives at Bayer: a personal view. Part I. Antiparasitics, sulfonamides, and antitubercular drugs. SIM News 57, 135-150 (2007).
79. Schneider, G. & Lindqvist, Y. Structural enzymology of biotin biosynthesis. FEBS Lett. 495, 7-11 (2001).
80. Grundy, W. E., Whitman, A. O., Rdzok, E. G., Hanes, M. E. & Sylvester, J. C. Actithiazic acid. I. Microbiological studies. Antibiot. Chemother. 2, 399-408 (1952).
81. Okami, Y., Kitahara, T., Hamada, M., Naganawa, H. & Kondo, S. Studies on a new amino acid antibiotic, amiclenomycin. J. Antibiot. 27, 656-664 (1974).
82. Kitahara, T., Hotta, K., Yoshida, M. & Okami, Y. Biological studies of amiclenomycin. J. Antibiot. 28, 215-221 (1975).
83. Mann, S., Marquet, A. & Ploux, O. Inhibition of 7, 8-diaminopelargonic acid aminotransferase by amiclenomycin and analogues. Biochem. Soc. Trans. 33, 802-805 (2005).
84. Eisenberg, M. A. & Hsiung, S. C. Mode of action of the biotin antimetabolites actithiazic acid and a-methyldethiobiotin. Antimicrob. Agents Chemother. 21, 5-10 (1982).
85. Shi, C. & Aldrich, C. C. Design and synthesis of potential mechanism-based inhibitors of the aminotransferase BioA involved in biotin biosynthesis. J. Org. Chem. 77, 6051-6058 (2012).
86. Park, S. W. et al. Evaluating the sensitivity of Mycobacterium tuberculosis to biotin deprivation using regulated gene expression. PLoS Pathog. 7, e1002264 (2011).
87. Soares da Costa, T. P. et al. Biotin analogues with antibacterial activity are potent inhibitors of biotin protein ligase. ACS Med. Chem. Lett. 3, 509-514 (2012).
88. Duckworth, B. P. et al. Bisubstrate adenylation inhibitors of biotin protein ligase from Mycobacterium tuberculosis. Chem. Biol. 18, 1432-1441 (2011).
89. Yi, X. & Maeda, N. Endogenous production of lipoic acid is essential for mouse development. Mol. Cell. Biol. 25, 8387-8392 (2005).
90. Christensen, Q. H., Hagar, J. A., O'Riordan, M. X. & Cronan, J. E. A complex lipoate utilization pathway in Listeria monocytogenes. J. Biol. Chem. 286, 31447-31456 (2011).
91. Spalding, M. D. & Prigge, S. T. Lipoic acid metabolism in microbial pathogens. Microbiol. Mol. Biol. Rev. 74, 200-228 (2010).
92. Reed, L. J., DeBusk, B. G., Gunsalus, I. C. & Hornberger, C. S. Jr. Crystalline a-lipoic acid; a catalytic agent associated with pyruvate dehydrogenase. Science 114, 93-94 (1951).
93. O'Riordan, M., Moors, M. A. & Portnoy, D. A. Listeria intracellular growth and virulence require host-derived lipoic acid. Science 302, 462-464 (2003).
94. Keeney, K. M., Stuckey, J. A. & O'Riordan, M. X. LplA1-dependent utilization of host lipoyl peptides enables Listeria cytosolic growth and virulence. Mol. Microbiol. 66, 758-770 (2007).
95. Pilatz, S. et al. Identification of Burkholderia pseudomallei genes required for the intracellular life cycle and in vivo virulence. Infect. Immun. 74, 3576-3586 (2006).
96. Macheroux, P., Kappes, B. & Ealick, S. E. Flavogenomics-a genomic and structural view of flavin-dependent proteins. FEBS J. 278, 2625-2634 (2011).
97. Decker, K. F. Biosynthesis and function of enzymes with covalently bound flavin. Annu. Rev. Nutr. 13, 17-41 (1993).
98. Mewies, M., McIntire, W. S. & Scrutton, N. S. Covalent attachment of flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) to enzymes: the current state of affairs. Protein Sci. 7, 7-20 (1998).
99. Bacher, A. et al. Biosynthesis of riboflavin. Vitam. Horm. 61, 1-49 (2001).
100. Koser, S. A. Vitamin Requirements of Bacteria and Yeasts (Charles C. Thomas, Springfield, IL, USA, 1968).
101. Bacher, A., Eberhardt, S. & Richter, G. in Escherichia coli and Salmonella (ed Neidhardt, F. C.) 657-664 (Am. Soc. Microbiol., Washington, DC, USA, 1996).
102. Morgunova, E. et al. Structural and thermodynamic insights into the binding mode of five novel inhibitors of lumazine synthase from Mycobacterium tuberculosis. FEBS J. 273, 4790-4804 (2006).
103. Otani, S. et al. Roseoflavin, a new antimicrobial pigment from Streptomyces. J. Antibiot. 27, 88-89 (1974).
104. Lee, E. R., Blount, K. F. & Breaker, R. R. Roseoflavin is a natural antibacterial compound that binds to FMN riboswitches and regulates gene expression. RNA Biol. 6, 187-194 (2009).
105. Mansjö, M. & Johansson, J. The riboflavin analog roseoflavin targets an FMN-riboswitch and blocks Listeria monocytogenes growth, but also stimulates virulence gene-expression and infection. RNA Biol. 8, 674-680 (2011).
106. Juri, N. et al. Formation of roseoflavin from 8-amino-and 8-methylamino-8-demethyl-D-riboflavin. J. Biochem. 101, 705-711 (1987).
107. Pedrolli, D. B. et al. The antibiotics roseoflavin and 8-demethyl-8-amino-riboflavin from Streptomyces davawensis are metabolized by human flavokinase and human FAD synthetase. Biochem. Pharmacol. 82, 1853-1859 (2011).
108. Cushman, M. et al. Design, synthesis, and biochemical evaluation of 1, 5, 6, 7-tetrahydro-6, 7-dioxo-9-D-ribitylaminolumazines bearing alkyl phosphate substituents as inhibitors of lumazine synthase and riboflavin synthase. J. Org. Chem. 70, 8162-8170 (2005).
109. Zhao, Y. et al. Discovery and development of the covalent hydrates of trifluoromethy-lated pyrazoles as riboflavin synthase inhibitors with antibiotic activity against Mycobacterium tuberculosis. J. Org. Chem. 74, 5297-5303 (2009).
110. Reddick, J. J. et al. The mechanism of action of bacimethrin, a naturally occurring thiamin antimetabolite. Bioorg. Med. Chem. Lett. 11, 2245-2248 (2001).
111. 1) biosynthesis and regulation: a rich source of antimicrobial drug targets? Int. J. Biol. Sci. 7, 41-52 (2011).
112. Khare, G., Kar, R. & Tyagi, A. K. Identification of inhibitors against Mycobacterium tuberculosis thiamin phosphate synthase, an important target for the development of anti-TB drugs. PLoS One 6, e22441 (2011).
113. Nodwell, M. B., Menz, H., Kirsch, S. F. & Sieber, S. A. Rugulactone and its analogues exert antibacterial effects through multiple mechanisms including inhibition of thiamine biosynthesis. ChemBioChem 13, 1439-1446 (2012).
114. Spry, C., Kirk, K. & Saliba, K. J. Coenzyme A biosynthesis: an antimicrobial drug target. FEMS Microbiol. Rev. 32, 56-106 (2008).
115. Ambady, A. et al. Evaluation of CoA biosynthesis proteins of Mycobacterium tuberculosis as potential drug targets. Tuberculosis 92, 521-528 (2012).
116. van der Westhuyzen, R. et al. The antibiotic CJ-15, 801 is an antimetabolite that hijacks and then inhibits CoA biosynthesis. Chem. Biol. 19, 559-571 (2012).
117. Lu, X., Zhang, H., Tonge, P. J. & Tan, D. S. Mechanism-based inhibitors of MenE, an acyl-CoA synthetase involved in bacterial menaquinone biosynthesis. Bioorg. Med. Chem. Lett. 18, 5963-5966 (2008).
118. Li, X. et al. Synthesis and SAR studies of 1, 4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett. 20, 6306-6309 (2010).
119. Zhou, Y. et al. Distribution of 16S rRNA methylases among different species of Gram-negative bacilli with high-level resistance to aminoglycosides. Eur. J. Clin. Microbiol. Infect. Dis. 29, 1349-1353 (2010).
120. Yang, J. et al. Diverse prevalence of 16S rRNA methylase genes armA and rmtB amongst clinical multidrug-resistant Escherichia coli and Klebsiella pneumoniae isolates. Int. J. Antimicrob. Agents 38, 348-351 (2011).
121. Li, J.-J. et al. Epidemic of Klebsiella pneumoniae ST11 clone coproducing KPC-2 and 16S rRNA methylase RmtB in a Chinese university hospital. BMC Infect. Dis. 12, 373 (2012).
122. Livermore, D. M. et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J. Antimicrob. Chemother. 66, 48-53 (2011).
123. 1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides. Antimicrob. Agents Chemother. 51, 4401-4409 (2007).
124. Wachino, J.-i. & Arakawa, Y. Exogenously acquired 16S rRNA methyltransferases found in aminoglycoside-resistant pathogenic Gram-negative bacteria: an update. Drug Resist Updat. 15, 133-148 (2012).
125. Wachino, J.-i. et al. RmtC introduces G1405 methylation in 16S rRNA and confers high-level aminoglycoside resistance on Gram-positive microorganisms. FEMS Micro-biol. Lett. 311, 56-60 (2010).
126. NDM-1-positive Enterobacteriaceae. Antimicrob. Agents Chemother. 55, 5403-5407 (2011).
127. 2A sequence. Nucleic Acids Res. 10, 4237-4245 (1982).
128. Connolly, K., Rife, J. P. & Culver, G. Mechanistic insight into the ribosome biogenesis functions of the ancient protein KsgA. Mol. Microbiol. 70, 1062-1075 (2008).
129. Weisblum, B. Erythromycin resistance by ribosome modification. Antimicrob. Agents Chemother. 39, 577-585 (1995).
130. Maravić, G. Macrolide resistance based on the Erm-mediated rRNA methylation. Curr. Drug Targets Infect. Disord. 4, 193-202 (2004).
131. Chung, W. O., Werckenthin, C., Schwarz, S. & Roberts, M. C. Host range of the ermF rRNA methylase gene in bacteria of human and animal origin. J. Antimicrob. Chemother. 43, 5-14 (1999).
132. Buriánková, K. et al. Molecular basis of intrinsic macrolide resistance in the Mycobacterium tuberculosis complex. Antimicrob. Agents Chemother. 48, 143-150 (2004).
133. Schmitz, F.-J. et al. Prevalence of macrolide-resistance genes in Staphylococcus aureus and Enterococcus faecium isolates from 24 European university hospitals. J. Antimicrob. Chemother. 45, 891-894 (2000).
134. Lina, G. et al. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. Antimicrob. Agents Chemother. 43, 1062-1066 (1999).
135. Melter, O. et al. Update on the major clonal types of methicillin-resistant Staphylo-coccus aureus in the Czech Republic. J. Clin. Microbiol. 41, 4998-5005 (2003).
136. Spiliopoulou, I., Petinaki, E., Papandreou, P. & Dimitracopoulos, G. erm(C) is the predominant genetic determinant for the expression of resistance to macrolides among methicillin-resistant Staphylococcus aureus clinical isolates in Greece. J Antimicrob. Chemother. 53, 814-817 (2004).
137. Portillo, A. et al. Macrolide resistance genes in Enterococcus spp. Antimicrob. Agents Chemother. 44, 967-971 (2000).
138. Shortridge, V. D. et al. Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and-resistant streptococci and staphylococci. Anti-microb. Agents Chemother. 46, 783-786 (2002).
139. Jalava, J., Kataja, J., Seppälä, H. & Huovinen, P. In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species. Antimicrob. Agents Chemother. 45, 789-793 (2001).
140. Liu, M. & Douthwaite, S. Activity of the ketolide telithromycin Is refractory to Erm monomethylation of bacterial rRNA. Antimicrob. Agents Chemother. 46, 1629-1633 (2002).
141. Smith, L. K. & Mankin, A. S. Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors. Antimicrob. Agents Chemother. 52, 1703-1712 (2008).
142. Witte, W. & Cuny, C. Emergence and spread of cfr-mediated multiresistance in staphylococci: an interdisciplinary challenge. Future Microbiol. 6, 925-931 (2011).
143. Morales, G. et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin. Infect. Dis. 50, 821-825 (2010).
144. Seral, C. et al. Nosocomial outbreak of methicillin-and linezolid-resistant Staphylo-coccus epidermidis associated with catheter-related infections in intensive care unit patients. Int. J. Med. Microbiol. 301, 354-358 (2011).
145. Gu, B., Kelesidis, T., Tsiodras, S., Hindler, J. & Humphries, R. M. The emerging problem of linezolid-resistant Staphylococcus. J. Antimicrob. Chemother. 68, 4-11 (2013).
146. Pournaras, S. et al. Linezolid dependence in Staphylococcus epidermidis bloodstream isolates. Emerg. Infect. Dis. 19, 129-132 (2013).
147. Wang, Y. et al. Detection of the staphylococcal multiresistance gene cfr in Proteus vulgaris of food animal origin. J. Antimicrob. Chemother. 66, 2521-2526 (2011).
148. Maravić, G., Bujnicki, J. M., Feder, M., Pongor, S. & Flögel, M. Alanine-scanning mutagenesis of the predicted rRNA-binding domain of ErmC redefines the substrate-binding site and suggests a model for protein-RNA interactions. Nucleic Acids Res. 31, 4941-4949 (2003).
149. Hajduk, P. J. et al. Novel inhibitors of Erm methyltransferases from NMR and parallel synthesis. J. Med. Chem. 42, 3852-3859 (1999).
150. Hanessian, S. & Sgarbi, P. W. M. Design and synthesis of mimics of S-adenosyl-L-homocysteine as potential inhibitors of erythromycin methyltransferases. Bioorg. Med. Chem. Lett. 10, 433-437 (2000).
151. Seidel-Rogol, B. L., McCulloch, V. & Shadel, G. S. Human mitochondrial transcription factor B1 methylates ribosomal RNA at a conserved stem-loop. Nat. Genet. 33, 23-24 (2003).
152. Chiang, P. K. et al. S-Adenosylmethionine and methylation. FA S E B J. 10, 471-480 (1996).
153. Struck, A.-W., Thompson, M. L., Wong, L. S. & Micklefield, J. S-Adenosyl-methionine-dependent methyltransferases: highly versatile enzymes in biocatalysis, biosynthesis and other biotechnological applications. ChemBioChem 13, 2642-2655 (2012).
154. Lu, S. C. & Mato, J. M. S-Adenosylmethionine in liver health, injury, and cancer. Physiol. Rev. 92, 1515-1542 (2012).
155. Zweygarth, E., Schillinger, D., Kaufmann, W. & Röttcher, D. Evaluation of sinefungin for the treatment of Try panosoma (Nannomonas) congolense infections in goats. Trop. Med. Parasitol. 37, 255-257 (1986).
156. Clancy, J. et al. Assays to detect and characterize synthetic agents that inhibit the ErmC methyltransferase. J. Antibiot. 48, 1273-1279 (1995).
157. Feder, M. et al. Virtual screening and experimental verification to identify potential inhibitors of the ErmC methyltransferase responsible for bacterial resistance against macrolide antibiotics. ChemMedChem 3, 316-322 (2008).
158. Schluckebier, G., Zhong, P., Stewart, K. D., Kavanaugh, T. J. & Abad-Zapatero, C. The 2.2 A structure of the rRNA methyltransferase ErmC' and its complexes with cofactor and cofactor analogs: implications for the reaction mechanism. J. Mol. Biol. 289, 277-291 (1999).
159. Giannattasio, R. B. & Weisblum, B. Modulation of Erm methyltransferase activity by peptides derived from phage display. Antimicrob. Agents Chemother. 44, 1961-1963 (2000).
160. Schluckebier, G., Labahn, J., Granzin, J. & Saenger, W. M.Ta q I: possible catalysis via cation-p interactions in N-specific DNA methyltransferases. Biol. Chem. 379, 389-400 (1998).
161. Baker M. R. Synthesis, Screening and Cocrystallization of Adenosine Based Inhibitors with Methyltransferases, ErmC and KsgA. (PhD thesis, Virginia Commonwealth Univ., 2011).
162. Alvesalo, J. K., Siiskonen, A., Vainio, M. J., Tammela, P. S. & Vuorela, P. M. Similarity based virtual screening: a tool for targeted library design. J. Med. Chem. 49, 2353-2356 (2006).
163. Baker, M. R., Zarubica, T., Wright, H. T. & Rife, J. P. Scintillation proximity assay for measurement of RNA methylation. Nucleic Acids Res. 37, e32 (2009).
164. Ogura, T. & Hiraga, S. Mini-F plasmid genes that couple host cell division to plasmid proliferation. Proc. Natl Acad. Sci. USA 80, 4784-4788 (1983).
165. Fozo, E. M. et al. Abundance of type I toxin-antitoxin systems in bacteria: searches for new candidates and discovery of novel families. Nucleic Acids Res. 38, 3743-3759 (2010).
166. Guglielmini, J. & Van Melderen, L. Bacterial toxin-antitoxin systems: translation inhibitors everywhere. Mob. Genet. Elements 1, 283-290 (2011).
167. Leplae, R. et al. Diversity of bacterial type II toxin-antitoxin systems: a comprehensive search and functional analysis of novel families. Nucleic Acids Res. 39, 5513-5525 (2011).
168. Yamaguchi, Y. & Inouye, M. Regulation of growth and death in Escherichia coli by toxin-antitoxin systems. Nat. Rev. Microbiol. 9, 779-790 (2011).
169. Ramage, H. R., Connolly, L. E. & Cox, J. S. Comprehensive functional analysis of Mycobacterium tuberculosis toxin-antitoxin systems: implications for pathogenesis, stress responses, and evolution. PLoS Genet. 5, e1000767 (2009).
170. Yamaguchi, Y., Park, J.-H. & Inouye, M. Toxin-antitoxin systems in bacteria and archaea. Annu. Rev. Genet. 45, 61-79 (2011).
171. Masuda, H., Tan, Q., Awano, N., Wu, K.-P. & Inouye, M. YeeU enhances the bundling of cytoskeletal polymers of MreB and FtsZ, antagonizing the CbtA (YeeV) toxicity in Escherichia coli. Mol. Microbiol. 84, 979-989 (2012).
172. Wang, X. et al. A new type V toxin-antitoxin system where mRNA for toxin GhoT is cleaved by antitoxin GhoS. Nat. Chem. Biol. 8, 855-861 (2012).
173. Unoson, C. & Wagner, E. G. A small SOS-induced toxin is targeted against the inner membrane in Escherichia coli. Mol. Microbiol. 70, 258-270 (2008).
174. Hayes, F. & Van Melderen, L. Toxins-antitoxins: diversity, evolution and function. Crit. Rev. Biochem. Mol. Biol. 46, 386-408 (2011).
175. Syed, M. A. & Lévesque, C. M. Chromosomal bacterial type II toxin-antitoxin systems. Can. J. Microbiol. 58, 553-562 (2012).
176. Hochman, A. Programmed cell death in prokaryotes. Crit. Rev. Microbiol. 23, 207-214 (1997).
177. Rice, K. C. & Bayles, K. W. Molecular control of bacterial death and lysis. Microbiol. Mol. Biol. Rev. 72, 85-109 (2008).
178. Arcus, V. L., McKenzie, J. L., Robson, J. & Cook, G. M. The PIN-domain ribonucleases and the prokaryotic VapBC toxin-antitoxin array. Protein Eng. Des. Sel. 24, 33-40 (2011).
179. Sat, B., Reches, M. & Engelberg-Kulka, H. The Escherichia coli mazEF suicide module mediates thymineless death. J. Bacteriol. 185, 1803-1807 (2003).
180. Zhang, Y. et al. MazF cleaves cellular mRNAs specifically at ACA to block protein synthesis in Escherichia coli. Mol. Cell. 12, 913-923 (2003).
181. Kolodkin-Gal, I. & Engelberg-Kulka, H. Induction of Escherichia coli chromosomal mazEF by stressful conditions causes an irreversible loss of viability. J. Bacteriol. 188, 3420-3423 (2006).
182. Bast, S. D., Mine, M. & Van Melderen, N. L. Chromosomal toxin-antitoxin systems may act as antiaddiction modules. J. Bacteriol. 190, 4603-4609 (2008).
183. Yang, M., Gao, C., Wang, Y., Zhang, H. & He, Z.-G. Characterization of the interaction and cross-regulation of three Mycobacterium tuberculosis
184. Williams, J. J., Halvorsen, E. M., Dwyer, E. M., DiFazio, R. M. & Hergenrother, P. J. Toxin-antitoxin (TA) systems are prevalent and transcribed in clinical isolates of Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. FEMS Microbiol. Lett. 322, 41-50 (2011).
185. Williams, J. J. & Hergenrother, P. J. Artificial activation of toxin-antitoxin systems as an antibacterial strategy. Trends Microbiol. 20, 291-298 (2012).
186. Lioy, V. S., Rey, O., Balsa, D., Pellicer, T. & Alonso, J. C. A toxin-antitoxin module as a target for antimicrobial development. Plasmid 63, 31-39 (2010).
187. Mutschler, H. & Meinhart, A. e/z systems: their role in resistance, virulence, and their potential for antibiotic development. J. Mol. Med. 89, 1183-1194 (2011).
188. Chopra, N., Agarwal, S., Verma, S., Bhatnagar, S. & Bhatnagar, R. Modeling of the structure and interactions of the B. anthracis antitoxin, MoxX: deletion mutant studies highlight its modular structure and repressor function. J. Comput.-Aided Mol. Des. 25, 275-291 (2011).
189. Lewis, K. Persister cells. Annu. Rev. Microbiol. 64, 357-372 (2010).
190. Lewis, K. Persister cells: molecular mechanisms related to antibiotic tolerance. Handb. Exp. Pharmacol. 211, 121-133 (2012).
191. Kint, C. I., Verstraeten, N., Fauvart, M. & Michiels, J. New-found fundamentals of bacterial persistence. Trends Microbiol. 20, 577-585 (2012).
192. Maisonneuve, E., Shakespeare, L. J., Jørgensen, M. G. & Gerdes, K. Bacterial persistence by RNA endonucleases. Proc. Natl Acad. Sci. USA 108, 13206-13211 (2011).
193. Kwan, B. W., Valenta, J. A., Benedik, M. J. & Wood, T. K. Arrested protein synthesis increases persister-like cell formation. Antimicrob. Agents Chemother. 57, 1468-1473 (2013).
194. Wagner, E. G. & Unoson, C. The toxin-antitoxin system tisB-istR1. Expression, regulation, and biological role in persister phenotypes. RNA Biol 9, 1513-1519 (2012).
195. Dörr, T., Vulic, M. & Lewis, K. Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS Biol. 8, e1000317 (2010).
196. Turchina, P. & Scheidel, W. Coin hoards speak of population declines in ancient Rome. Proc. Natl Acad. Sci. USA 106, 17276-17279 (2009).
197. Paine, R. R. & Storey, G. R. in Urbanism in the Preindustrial World: Cross-Cultural Approaches (ed Story, G. R.) 69-85 (University of Alabama Press, Tuscaloosa, AL USA, 2006).
198. Cunha, C. B. & Cunha, B. A. in Paleomicrobiology. Past Human Infections (eds Raoult, D. & Drancourt, M.) 1-20 (Springer-Verlag, Berlin Heidelberg, Germany 2008).
199. Gilbert, D. N. et al. The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 50, 1081-1083 (2010).
200. Shapiro, S. & Caspi, E. The steric course of enzymic hydroxylation at primary carbon atoms. Tetrahedron 54, 5005-5040 (1998).